3.9 Article

Amyloid-beta Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease

Journal

MOUNT SINAI JOURNAL OF MEDICINE
Volume 77, Issue 1, Pages 43-49

Publisher

WILEY
DOI: 10.1002/msj.20160

Keywords

Alzheimer's disease; amyloid-beta peptide; dementia; oligomer

Funding

  1. NIA [P01 AG10491, P50 AG05138]
  2. Cure Alzheimer's Fund
  3. NATIONAL INSTITUTE ON AGING [P01AG010491, P50AG005138] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Alzheimer's disease is the most common form of senile dementia. Although the amyloid-beta peptide was identified in 1984 as the major constituent of the senile plaques that characterize the disease, accumulating evidence indicates that the plaque density does not correspond well to the concurrent disease state. In order to resolve this disconnect, a number of recent Studies have shifted away from the senile plaque and classical fibrillar forms of amyloid toward a less well structured species as the proximate neurotoxic factor underlying cognitive failure in Alzheimer's disease: soluble amyloid-beta peptide oligomer (also known as the amyloid-beta peptide-derived diffusible ligand). Paradoxically, several Studies in the last 2 years have shown that picomolar levels of amyloid-beta peptide have neutral activity or perhaps even an essential role in learning and memory. Here we highlight some of the key observations underlying the growing focus on the amyloid-beta peptide oligomer. Mt Sinai J Med 77:43-49, 2010. (C) 2010 Mount Sinai School of Medicine

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available